Physician profile

Max Kopitnik

Trauma Surgery · Waco, TX

NPI 1588027551

$3,673.79

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$3,000.00
Food and Beverage$281.46
Travel and Lodging$231.52

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $3,353.35 2023 Davinci Xi, Da Vinci Surgical System
Allergan, INC. $128.37 2020
Integra Lifesciences Corporation $77.00 2022-2023 Integra, Primatrix, Integra Dermal Regeneration Template
Tela Bio, INC. $64.40 2024 Ovitex 2s
Csl Behring $19.06 2020
Smith+Nephew, INC. $17.08 2024 Collagenase Santyl
Davol INC. $14.53 2023 Phasix Mesh

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Max Kopitnik

$3,673.79

in general payments reported 2019-2025

Years
2020-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/7233440/max-kopitnik

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.